LT2782602T - Nukleotidas dims0-150, skirtas lėtinio aktyvaus opinio kolito gydymui - Google Patents

Nukleotidas dims0-150, skirtas lėtinio aktyvaus opinio kolito gydymui

Info

Publication number
LT2782602T
LT2782602T LTEP12790904.2T LT12790904T LT2782602T LT 2782602 T LT2782602 T LT 2782602T LT 12790904 T LT12790904 T LT 12790904T LT 2782602 T LT2782602 T LT 2782602T
Authority
LT
Lithuania
Prior art keywords
dims0
cololis
nucleotide
treatment
lower active
Prior art date
Application number
LTEP12790904.2T
Other languages
English (en)
Lithuanian (lt)
Inventor
Charlotte Admyre
Arezou Zargari
Oliver Von Stein
Petra Von Stein
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Publication of LT2782602T publication Critical patent/LT2782602T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEP12790904.2T 2011-11-25 2012-11-23 Nukleotidas dims0-150, skirtas lėtinio aktyvaus opinio kolito gydymui LT2782602T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11190826.5A EP2596806A1 (en) 2011-11-25 2011-11-25 Method for prevention of colectomy
US201261595230P 2012-02-06 2012-02-06
PCT/EP2012/073501 WO2013076262A1 (en) 2011-11-25 2012-11-23 Method for prevention of colectomy

Publications (1)

Publication Number Publication Date
LT2782602T true LT2782602T (lt) 2019-10-10

Family

ID=45094516

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12790904.2T LT2782602T (lt) 2011-11-25 2012-11-23 Nukleotidas dims0-150, skirtas lėtinio aktyvaus opinio kolito gydymui

Country Status (16)

Country Link
US (3) US9492516B2 (cg-RX-API-DMAC7.html)
EP (3) EP2596806A1 (cg-RX-API-DMAC7.html)
JP (2) JP6193248B2 (cg-RX-API-DMAC7.html)
CA (1) CA2892203C (cg-RX-API-DMAC7.html)
CY (1) CY1122089T1 (cg-RX-API-DMAC7.html)
DK (1) DK2782602T3 (cg-RX-API-DMAC7.html)
ES (1) ES2745677T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191723T1 (cg-RX-API-DMAC7.html)
HU (1) HUE046154T2 (cg-RX-API-DMAC7.html)
LT (1) LT2782602T (cg-RX-API-DMAC7.html)
PL (1) PL2782602T3 (cg-RX-API-DMAC7.html)
PT (1) PT2782602T (cg-RX-API-DMAC7.html)
RS (1) RS59358B1 (cg-RX-API-DMAC7.html)
SI (1) SI2782602T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900527T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013076262A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881808C (en) * 2013-07-05 2021-08-17 Sony Corporation Transmission apparatus, transmission method, reception apparatus, and reception method
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
GB201707503D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3
GB201807312D0 (en) * 2018-05-03 2018-06-20 Index Pharmaceuticals Ab Formulation
GB201818579D0 (en) * 2018-11-14 2018-12-26 Index Pharmaceuticals Ab New therapy
GB201912191D0 (en) * 2019-08-24 2019-10-09 Index Pharmaceuticals Ab New therapy
EP4147688A1 (en) * 2021-09-09 2023-03-15 InDex Pharmaceuticals AB Enema formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
JP4359654B2 (ja) 1996-01-30 2009-11-04 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 抗原特異的免疫応答を生起させる遺伝子発現ベクターおよびその使用方法
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US6809193B2 (en) * 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
AU2006205571B2 (en) 2005-01-13 2012-03-22 Progenika Biopharma, S.A. Methods and products for in vitro genotyping
JPWO2006132204A1 (ja) 2005-06-06 2009-01-08 アンジェスＭｇ株式会社 転写因子デコイ
EP1904077B1 (en) 2005-07-01 2009-08-12 Index Pharmaceuticals AB Modulating responsiveness to steroids
ES2450593T3 (es) 2005-07-01 2014-03-25 Index Pharmaceuticals Ab Método inmunoestimulante
US8637479B2 (en) 2008-11-04 2014-01-28 Index Pharmaceuticals Ab Compounds and methods for the treatment of inflammatory diseases of the CNS

Also Published As

Publication number Publication date
JP2017061508A (ja) 2017-03-30
CA2892203C (en) 2021-11-16
RS59358B1 (sr) 2019-11-29
SMT201900527T1 (it) 2019-11-13
PL2782602T3 (pl) 2019-12-31
CA2892203A1 (en) 2013-05-30
US20150004187A1 (en) 2015-01-01
JP6318221B2 (ja) 2018-04-25
HRP20191723T1 (hr) 2019-12-13
US9795627B2 (en) 2017-10-24
US9492516B2 (en) 2016-11-15
ES2745677T3 (es) 2020-03-03
WO2013076262A1 (en) 2013-05-30
US20170014442A1 (en) 2017-01-19
EP2782602B1 (en) 2019-06-26
DK2782602T3 (da) 2019-09-30
JP6193248B2 (ja) 2017-09-06
EP2596806A1 (en) 2013-05-29
SI2782602T1 (sl) 2019-11-29
HUE046154T2 (hu) 2020-02-28
JP2015504438A (ja) 2015-02-12
EP2782602A1 (en) 2014-10-01
US20180015117A1 (en) 2018-01-18
EP3556403A1 (en) 2019-10-23
CY1122089T1 (el) 2020-11-25
PT2782602T (pt) 2019-10-14

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
HUS1900007I1 (hu) Kiméra, antigénreceptor-módosított T-sejt alkalmazása rák kezelésére
LT2887944T (lt) Alopregnanolonas, skirtas atsparios epileptinės būklės gydymui
LT2558105T (lt) Bardoksolono metilas, skirtas nutukimo gydymui
BR112013024491A2 (pt) neuroestimulador.
LT3026064T (lt) Antikūnai, skirti vėžio gydymui, ekspresuojantys klaudiną 6
PT2683384E (pt) Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
LT3406251T (lt) Piruvatkinazės aktyvatoriai, skirti panaudoti terapijai
LT2782602T (lt) Nukleotidas dims0-150, skirtas lėtinio aktyvaus opinio kolito gydymui
EP2748299A4 (en) Targeting microbubbles
EP2688690A4 (en) ACTIVE ELECTROADHESION CLEANING
BR112013033974A2 (pt) terapia de combinação
CO6900134A2 (es) Tratamiento de mieloma múltiple
SI2602805T1 (sl) Ohišje za napravo za prenapetostno zaščito in ustrezna naprava za prenapetostno zaščito
CO6801765A2 (es) Isoxazolinas como agentes terapéuticos
LT2812013T (lt) Kompozicija, skirta džs gydymui
IL227747A0 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
FR2978994B1 (fr) .
ME02908B (me) Supstituisani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije
EP2752241A4 (en) CATALYST
IL228729A0 (en) Treatment regimens
HUE036048T2 (hu) Gyógyszerészetileg aktív vegyületek
BR112013020866A2 (pt) combinações de compostos ativos
ITTO20110857A1 (it) Procedimento per la produzione di cicloesanonossina.
DK2694056T3 (da) Terapeutisk behandling